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previous episode(s) of constipation, previous or current 
anal fissure, painful bowel movements, and bleeding 
associated with hard stools. 
Diagnosing idiopathic constipation
If the child or young person has constipation take a history 
and exclude underlying causes.
• “Red flag” findings and diagnostic clues to an 
underlying condition: constipation reported from birth 
or first few weeks of life, failure to pass meconium 
or delay in passing meconium (more than 48 hours 
after birth in term baby), long narrow ribbon-like 
stools (more likely in a child under 1 year), previously 
unknown or undiagnosed weakness in legs, locomotor 
delay, and abdominal distension with vomiting. 
• Diagnostic clues to idiopathic constipation: 
constipation that starts after a few weeks of life with 
obvious precipitating factors (fissure, change of diet, 
or infections in children under 1 year; fissure, change 
of diet, timing of potty or toilet training, and an acute 
event such as infection, moving house, starting 
nursery or school, fears and phobias, major change 
in family, taking medicine in children over 1 year); 
normal passage of meconium (within 48 hours after 
birth in term baby); child generally well, with normal 
weight and height; no neurological problems in legs; 
normal locomotor development; history of poor diet 
or insufficient fluid intake (or both); and changes in 
infant formula or weaning in child under 1 year. 
Perform a physical examination and exclude underlying 
causes.
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Constipation is described as “the subjective complaint of pas-
sage of abnormally delayed or infrequent passage of dry, hard-
ened faeces, often accompanied by straining and/or pain.”1 
Constipation is common in childhood, is rarely life threat-
ening, and therefore might be expected to have little effect 
on healthcare provision. The reality is somewhat different, 
however. Symptoms become chronic in more than a third of 
patients, causing great discomfort, and many children need 
medical treatment and nursing care.2-5 Lack of understand-
ing about the condition, delayed diagnosis, and suboptimal 
treatment and support contribute to ongoing symptoms and 
multiple medical consultations.6 Social costs include children 
missing school, being excluded from peer group activities, and 
feeling that they cannot tell their friends about their condition. 
This article summarises the most recent recommendations 
from the National Institute for Health and Clinical Excellence 
(NICE) on the care and management of children and young 
people with idiopathic constipation.7
Recommendations
NICE recommendations are based on systematic reviews 
of best available evidence and explicit consideration of 
cost effectiveness. When minimal evidence is available, 
recommendations are based on the Guideline Develop-
ment Group’s experience and opinion of what constitutes 
good practice. Evidence levels for the recommendations 
are in the full version of this article on bmj.com.
establishing the presence of constipation
Establish whether constipation is present during history 
taking. Two or more of the following findings indicate 
constipation:
• Children under 1 year: fewer than three complete stools 
a week (fig 1; this does not apply to exclusively breast 
fed babies after 6 weeks of age), hard large stools, 
“rabbit droppings” or “nuts” (type 1, fig 1), distress 
on defecating, bleeding associated with hard stools, 
straining, previous episode(s) of constipation, and 
previous or current anal fissure. 
• Children or young people over 1 year: fewer than three 
complete stools per week (see Bristol stool form scale), 
overflow soiling, rabbit droppings or nuts (fig 1), 
large infrequent stools that can block the toilet, poor 
appetite that improves with passage of a large stool, 
waxing and waning of abdominal pain with passage 
of stools, evidence of retentive posturing, anal pain, 
Type 1
Type 2
Type 3
Type 4
Type 5
Type 6
Type 7
Separate hard lumps, like nuts (hard to pass) 
Sausage shaped but lumpy
Like a sausage but with cracks on its surface
Like a sausage or snake, smooth and soft
Soft blobs with clear cut edges (passed easily)
Fluffy pieces with ragged edges, a mushy stool
Watery, no solid pieces; entirely liquid
Fig 1 | Bristol stool form scale. Adapted, with permission, from 
the NICE guidelines7
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the bottom of); scoliosis; deformity in lower limbs, 
such as talipes; abnormal neuromuscular signs in 
lower limbs not explained by any existing condition 
(such as cerebral palsy); and abnormal lower limb 
reflexes. 
• Diagnostic clues to idiopathic constipation: normal 
appearance of anus and surrounding area, soft flat 
abdomen or distension that can be explained because 
of age or excess weight, normal appearance of the skin 
and anatomical structures of lumbosacral and gluteal 
regions, normal gait, normal tone and strength in 
lower limbs, and normal lower limb reflexes (perform 
only if red flags in history or examination suggest new 
onset neurological impairment). 
If any red flag findings are present, do not treat for consti-
pation. Instead, refer urgently to a healthcare professional 
with experience in the specific aspect of child health that is 
causing concern. 
Do not perform a digital rectal examination unless you are 
a healthcare professional competent to interpret features of 
anatomical abnormalities.
In the absence of red flags, inform the child or young per-
son and his or her parents or carers of a positive diagnosis 
of idiopathic constipation and also that underlying causes 
have been excluded by the history and physical examination. 
Reassure them that a suitable treatment is available, but that 
it may take several months for the condition to resolve.
Treatment of faecal impaction (disimpaction)
Assess all children with idiopathic constipation for faecal 
impaction, including those who were referred to the relevant 
services because of red flags but who had no findings of con-
cern on further investigation. Use both history taking and 
physical examination to diagnose faecal impaction—looking 
for overflow soiling, faecal mass palpable abdominally, and, 
if indicated, rectally. The presence of one or both of these on 
physical examination together with the history is indicative 
of impaction.
If indicated, offer this oral regimen for disimpaction:
• Polyethylene glycol 3350 plus electrolytes (which may 
be mixed with a cold drink), using an escalating dose 
regimen (see fig 2) as first line treatment. 
• If this does not lead to disimpaction after two weeks, 
add a stimulant laxative. 
• If the first line treatment is not tolerated, substitute a 
stimulant laxative singly or with an osmotic laxative 
such as lactulose (fig 2).
• Inform families that treatment can initially increase 
symptoms of soiling and abdominal pain.
ongoing maintenance treatment
Offer the following treatments:
• Polyethylene glycol 3350 plus electrolytes (fig 2) as 
the first line treatment; adjust the dose according to 
symptoms and response.
• If this does not work, add a stimulant laxative (fig 2). 
• If the first line treatment is not tolerated, substitute 
a stimulant laxative. Add another laxative such as 
lactulose or docusate (fig 2) if stools are hard. 
• Continue laxatives at maintenance dose for several 
weeks after regular bowel habit is established; 
• Red flag findings and diagnostic clues to an underlying 
condition: abnormal appearance, position, or patency 
of anus (fistulas, bruising, multiple fissures, tight or 
patulous anus, anteriorly placed anus, absent anal 
wink); gross abdominal distension; asymmetry or 
flattening of the gluteal muscles; evidence of sacral 
agenesis; discoloured skin, naevi, or sinuses; hairy 
patch; lipoma; central pit (dimple that you cannot see 
Unless stated otherwise, doses are those recommended by the British National Formulary for Children (BNFC) 2009. Informed consent should
   be obtained and documented whenever drugs or doses are prescribed that are different from those recommended by the BNFC.
* At the time of publication (May 2010) Movicol Paediatric Plain is the only macrogol licensed for children under 12 years that includes electrolytes.
    It does not have UK marketing authorisation for use in faecal impaction in children under 5 years, or for chronic constipation in children under
   2 years. Informed consent should be obtained and documented. Movicol Paediatric Plain is the only macrogol licensed for children under
   12 years that is also unflavoured.
†Elixir, licensed for use in children (age range not specified by manufacturer). Perles not licensed for use in children under 4 years.
   Informed consent should be obtained and documented.
‡Dulcolax tablets which contain bisacodyl as the main ingredient should not be confused with Dulcolax perles which contain sodium picosulfate.
§ Syrup not licensed for use in children under 2 years. Informed consent should be obtained and documented.
¶ Adult oral solution and capsules not licensed for use in children under 12 years. Informed consent should be obtained and documented.
Laxatives
Polyethylene glycol
3350 + electrolytes
Recommended doses (all drugs listed below are given by mouth unless stated otherwise)
Macrogols
Paediatric formula
Oral powder, Macrogol 3350 (polyethylene glycol 3350)* 6.563 g, sodium bicarbonate
  89.3 mg, sodium chloride 175.4 mg, potassium chloride 25.1 mg in each sachet (unflavoured)
  Disimpaction 
  • Child under 1 year: ½ to 1 sachet daily (non-BNFC recommended dose)
  • Child 1–5 years: 2 sachets on 1st day, then 4 sachets daily for 2 days, then 6 sachets daily
       for 2 days, then 8 sachets daily (non-BNFC recommended dose)
  • Child 5–12 years: 4 sachets on 1st day, then increased in steps of 2 sachets daily to
       maximum of 12 sachets daily (non-BNFC recommended dose)
  Ongoing maintenance (chronic constipation, prevention of faecal impaction) 
  • Child under 1 year: ½ to 1 sachet daily (non-BNFC recommended dose)
  • Child 1–6 years: 1 sachet daily; adjust dose to produce regular soft stools
       (maximum 4 sachets daily) (for children under 2, non-BNFC dose)
  • Child 6–12 years: 2 sachets daily; adjust dose to produce regular soft stools
       (maximum 4 sachets daily)
Adult formula
Oral powder, Macrogol 3350 (polyethylene glycol 3350) 13.125 g, sodium bicarbonate
  178.5 mg, sodium chloride 350.7 mg, potassium chloride 46.6 mg in each sachet
  (unflavoured)
  Disimpaction 
  • Child/young person 12–18 years: 4 sachets on 1st day, then increased in steps of
      2 sachets daily to maximum of 8 sachets daily (non-BNFC recommended dose)
  Ongoing maintenance (chronic constipation, prevention of faecal impaction) 
  • Child/young person 12–18 years: 1–3 sachets daily in divided doses adjusted according
      to response; maintenance, 1–2 sachets daily
Lactulose
Osmotic laxatives
• Child 1 month to 1 year: 2.5 ml twice daily, adjusted according to response
• Child 1–5 years: 2.5–10 ml twice daily, adjusted according to response
     (non-BNFC recommended dose)
• Child/young person 5–18 years: 5–20 ml twice daily, adjusted according to response
     (non-BNFC recommended dose)
Sodium picosulfate†
Stimulant laxatives
Non-BNFC recommended doses
Elixir (5 mg/5 ml)
• Child 1 month to 4 years: 2.5–10 mg once a day
• Child/young person 4–18 years: 2.5–20 mg once a day
Non-BNFC recommended dose
Perles (1 tablet = 2.5 mg)
Child/young person 4–18 years: 2.5–20 mg once a day
Docusate sodium¶ • Child 6 months–2 years: 12.5 mg three times daily (use paediatric oral solution)
• Child 2–12 years: 12.5–25 mg three times daily (use paediatric oral solution)
• Child/young person 12–18 years: up to 500 mg daily in divided doses
Bisacodyl‡ Non-BNFC recommended doses
By mouth
• Child/young person 4–18 years: 5–20 mg once daily
By rectum (suppository)
• Child/young person 2–18 years: 5–10 mg once daily
Senna§ Senna syrup (7.5 mg/5 ml)
• Child 1 month to 4 years: 2.5–10 ml once daily
• Child/young person 4–18 years: 2.5–20 ml once daily
Senna (non-proprietary) (1 tablet = 7.5 mg)
• Child 2–4 years: ½ to 2 tablets once daily 
• Child 4–6 years: ½ to 4 tablets once daily
• Child/young person 6–18 years: 1–4 tablets once daily
Fig 2 | Recommended doses of laxatives for the treatment of idiopathic constipation in children
1242   BMJ | 5 June 2010 | VoluMe 340
PRACTICE
outperformed traditional advice giving in 80% of studies.3 
With practice, time can be saved by avoiding unproduc-
tive discussion and by using rapid engagement to focus 
on the changes that make a difference.
this may take several months. Children who are 
undergoing toilet training should remain on 
laxatives until toilet training is well established. 
• Do not stop laxatives abruptly: gradually reduce the 
dose over a period of months in response to stool 
consistency and frequency. Some children and 
young people may require laxatives for several years.
Diet and lifestyle interventions
Do not use dietary interventions alone as first line treatment 
for idiopathic constipation.
Treat with laxatives and a combination of the following:
• Negotiated and non-punitive behavioural interventions 
suited to the child’s stage of development. These could 
include scheduled toileting and support to establish a 
regular bowel habit, maintenance and discussion of a 
bowel diary, information on constipation, and use of 
encouragement and reward systems. 
• Dietary modifications to ensure a balanced diet and a 
sufficient intake of fluids. 
Information and support
Offer children and young people and their families a point of 
contact with specialist healthcare professionals, including 
school nurses, who can give ongoing support. 
Overcoming barriers
Improving awareness and understanding among healthcare 
professionals, children with constipation, and their families 
about the condition and its management will reduce miscon-
ceptions and negativity about diagnosis and treatment. An 
emphasis on recommended regimens for disimpaction and 
maintenance, how to reduce medication, and simple behav-
ioural and lifestyle interventions, together with a reduction in 
the use of invasive investigations and interventions, will help 
to improve outcomes, reduce discomfort, and refocus on the 
positive results of optimal treatment and care.
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Motivational interviewing has been shown 
to promote behaviour change in a wide 
range of healthcare settings
Discussion about change occurs in almost every branch 
of medicine, and goes beyond the “big four” lifestyle 
habits (smoking, excessive drinking, lack of exercise, 
and unhealthy diet), to also include the use of aids, 
devices, or medicines. Patients often seem ambivalent or 
unmotivated, and clinicians typically try to advise them 
to change, using a directing style, which in turn gener-
ates resistance or passivity in  the patient (see box 1). 
Motivational interviewing is an alternative approach to 
discussing behaviour change that fosters a constructive 
doctor-patient relationship and leads to better outcomes 
for patients.1
Motivational interviewing involves helping patients to 
say why and how they might change, and is based on the 
use of a guiding style.2 A recent systematic review that 
included 72 studies found that motivational interviewing 
KEy POInTs
Simply giving patients advice to change is often 
unrewarding and ineffective
Motivational interviewing uses a guiding style to engage 
with patients, clarify their strengths and aspirations, 
evoke their own motivations for change, and promote 
autonomy of decision making
You can learn motivational interviewing in three steps: 
practise a guiding rather than directing style; develop 
strategies to elicit the patient’s own motivation to 
change; and refine your listening skills and respond by 
encouraging change talk from the patient
Motivational interviewing has been shown to promote 
behaviour change in various healthcare settings and can 
improve the doctor-patient relationship and the efficiency 
of the consultation
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How best to do it
Step 1: practise the guiding style
Among the broad communication styles commonly used 
to address patients’ problems are directing, guiding, and 
following.2 Although each is appropriate to certain situa-
tions in everyday practice, a guiding style is best suited to 
consultations about change. When this topic comes up, 
shift your stance from that of a director to that of a well 
informed guide, and follow three principles: engage with 
and work in collaboration with patients, emphasise their 
autonomy over decision making, and elicit their motivation 
for change. You retain control over the direction and struc-
ture of the consultation and provide information as needed, 
but you ensure that your patients retain responsibility for 
change. Box 1 shows the contrast in styles between direct-
ing and guiding.
Use three core skills—asking, listening, and informing—
in the service of this guiding style to draw out your patients’ 
ideas and solutions.2 This shows that you want to know 
about and respect their ability to make sound decisions.
• “Ask” open ended questions—invite the patient to 
consider how and why they might change;
• “Listen” to understand your patient’s experience—
“capture” their account with brief summaries or 
reflective listening statements such as “quitting 
smoking feels beyond you at the moment”; these 
express empathy, encourage the patient to elaborate, 
and are often the best way to respond to resistance;
• “Inform”—by asking permission to provide 
information, and then asking what the implications 
might be for the patient.
Once you have practised these three skills, and once you 
feel comfortable with the shift from director to guide, you 
can add to your toolbox a set of strategies containing spe-
cific questions that are suited to different circumstances.
Step 2: add useful strategies to your toolbox
Motivational interviewing aims to elicit the motivation to 
change from the patient, rather than to try to instil this in 
them; it also aims to work with their strengths rather than just 
talk about problems and weaknesses. Different strategies are 
available to achieve these aims in a guiding style, eliciting the 
what, why, and how of change from the patient. This “menu 
of strategies”4 has been used successfully among college stu-
dents to reduce use of alcohol, tobacco, and cannabis.5
Agenda setting (what to change?)
Patients often face more than one option for change. 
In agenda setting, rather than impose your priority on 
patients, you conduct an overview by inviting them to 
select an issue or behaviour that they are most ready and 
able to tackle, feeling free also to express your own views.2 
For example, to reach agreement about what to deal with 
in the consultation you might say: “That’s very helpful. Are 
you more ready to focus on eating or on increased activity? 
Or is there some other topic that you would prefer to talk 
about? I’d like to talk about those test results at some point, 
but what makes sense to you right now?”
Pros and cons (why change?)
It is normal and common for patients to feel in two minds 
about both the status quo and change. It can be helpful to 
invite them to say how they see the pros and cons of a situ-
ation. Then your next step is to ask them to clarify whether 
change is a possibility (box 2).
Assess importance (why) and confidence (how)
To be efficient you need to spend time where it is most 
needed. Those who are not convinced of the importance 
of change are unlikely to benefit from advice about how 
to change, and a focus on the why of change is pointless if 
the main issue is how to achieve it. This focused strategy 
(box 3) has produced successful outcomes in the smoking 
field,6 where a recent review also provides support for the 
efficacy of motivational interviewing.7
Exchange information
One of the first successful studies of motivational interview-
ing placed listening at the centre during feedback of test 
results.8 This gave rise to the “elicit-provide-elicit” strat-
egy (box 4), in which a guiding style is used to encourage 
patients to clarify the personal implications of information 
that you provide.
Box 2 | Seeing the pros and cons 
“I want to try to understand your smoking better from your perspective, both the benefits 
for you and the drawbacks. Can I ask you firstly what you like about your smoking?” (Patient 
responds. Use your curiosity to elicit a good understanding.)
“Now can I ask you what you don’t like about your smoking?” (Patient responds. 
Remember it’s their experience that counts, so avoid offering your perspective for the time 
being.)
(Then you summarise both sides, as briefly as possible, capturing the words and phrases 
that the patient came up with.) “OK, so let’s see if I have this right? You like the fact that 
smoking helps you unwind and, addicted or not, you like that first smoke in the morning. 
On the other hand, your main concern is about its effect on your health. Is that about right? 
OK.”
 (Then you invite the patient to consider the next step.) “So where does that leave you 
now?” (Patient usually describes readiness and any need for advice or information.)
Box 1| Contrasting styles 
Directing style: “OK, so your weight is putting your health at serous risk. You already have early 
diabetes. (Patient often resists at this point.) . . . Overweight is conceptually very simple, if you 
think about it. Too much in, not enough out. So you need to eat less and exercise more. There 
no way you can get around that simple fact.” (Patient replies with a “yes, but . . .” argument.)
Guiding style: “OK, let’s have a look at this together and see what you think. From my side, 
losing some weight and getting more exercise will help your diabetes and your health, but 
what feels right for you? (Patient often expresses ambivalence at this point.) . . . So you can see 
the value of these things, but you struggle to see how you can succeed at this point in time. 
OK. It’s up to you to decide when and how to make any changes. I wonder, what sort of small 
changes might make sense to you?” (Patient says how change might be possible.)
Box 3 | Assessing importance and confidence
“Would you mind if we took a moment to see exactly 
how you feel about using these tablets?” (An invitation 
promotes collaboration and patient autonomy.)
“How important is taking this medicine for you right 
now?” (Elicit a brief review of patient’s feelings, fears, and 
aspirations, then ask:) “How confident do you feel about 
taking these tablets regularly?” (Elicit, and then summarise 
patient’s view of importance and confidence.) 
(Then tailor your next step accordingly—for example, if 
importance is low, consider something like:) “Well, do you 
mind if I just give you some information about how these 
tablets might help, but it will be up to you to decide in the 
end.” (Emphasising autonomy always helps.)
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Make decisions about change (setting goals)
Goals and targets for change that come only from your side 
are often met with “Yes, but. . .” explanations about why 
they will not work from the patient. Box 5 shows how you 
can, if the patient is ready for it, use a guiding style to elicit 
practical solutions from the patient and offer suggestions 
from your side as well.
Step 3: respond skilfully to patients’ language
You can refine your skills further by paying attention to 
the language that patients use.9 You will notice that they 
talk about why or how they might change (this is called 
change talk)—“I guess I should take my medicine more 
regularly”; “I want to quit smoking”; “I am going to eat 
less fried food”—or about the opposite: “I don’t like tab-
lets”; “I enjoy my smoking”; “I’ve never succeed in losing 
weight.” You can choose whether to elicit change talk or 
not. The assumption is that if you do, motivation to change 
will be enhanced, and subsequent change is more likely 
take place.9 Box 6 shows how a doctor elicits change talk 
and responds to it with further listening. Many of the ques-
tions shown in step 2 are useful because they elicit change 
talk—for example, “How important is it for you to take this 
medicine?”
One line of research has been to examine whether moti-
vational interviewing improves outcomes. A recent meta-
analysis of 119 studies concluded that it exerts a small but 
positive effect across a wide range of problem domains, 
but not in all.10 Another line of research has been to study 
language and change talk. For example, if people strug-
gling with alcohol and other drugs offer more change talk 
in counselling, their outcomes in regard to substance use 
are better11-13; moreover, practitioners who are competent 
in motivational interviewing elicit more change talk, inde-
pendent of the motivation of the patient.11
What are the challenges?
Any skilful task in medicine takes time to learn. Training, 
supervision, and feedback on performance will allow you 
to save time by using efficient questions suited to your 
personality, the patient, and the setting (see box 6). Moti-
vational interviewing has been shown to be effective in set-
tings where time constraints are paramount, like accident 
and emergency departments.14 15 
The biggest challenge is usually with the shift in style 
and attitude involved. This includes letting go of what has 
been called the “righting reflex,”2 the tendency to iden-
tify a problem and solve it for the patient (see box 1), and 
instead, enabling the patient to do this work for themselves. 
This can leave you feeling that you will lose control of the 
consultation. We suggest that you retain control of the 
overall direction of the consultation, and hand over to the 
patient control about the what, why, and how of change. 
You certainly can and should offer your views and exper-
tise, but within a style that is collaborative and emphasises 
the patient’s freedom to make any final decision.
Conclusion
Motivational interviewing is not a quick fix method, let 
alone a set of clever techniques for getting patients to do 
what they otherwise would not want to do.16 It is not done 
Box 4 | Information exchange 
“OK so can I check your understanding of the situation? What do you know about the risks 
of being overweight?” (Elicit understanding.) . . . “Well you are right about it being very 
common and that people are generally living longer, but as you say it does put an extra strain 
on the heart and causes diabetes, which again affects the heart, kidney, and so on. It also 
causes high blood pressure.” (Provide information.) “OK, now can I ask, how do you think 
this information applies to you?” (Elicit patient’s interpretation.)
Box 5 | Making decisions 
“It sounds like you really want to try quitting smoking, but you’re struggling with imagining 
how you can do it.” (Summarising the patient’s situation.)
“It will be up to you to decide when and how to do it (emphasising the patient’s freedom 
of choice) but I am wondering how do you see yourself succeeding with this?” (Inviting the 
patient to envision change. Patient responds, usually identifying main challenges.)
“So you are hoping you can find a way of breaking through the withdrawal period. 
(Listening, in response to what patient has said.) There are all sorts of quitting aids that 
others have found useful, but what makes sense to you? (Inviting patient to clarify what will 
be helpful.) Or maybe you want to bring your husband down to talk with us so we can all 
make a plan together?” (Patient clarifies what will be helpful, and the discussion narrows 
down in favour of a plan that is agreed jointly.)
Box 6 | Eliciting change talk 
A young refugee with HIV-AIDS is pregnant and faces the need to take antiretroviral therapy 
appropriately and make lifestyle changes.
Doctor: How are things at home? 
Mother: Well my husband agrees I should take the pills to have a healthy baby but he 
doesn’t want to use condoms. 
Doctor: What would be most helpful for us to start talking about? Is it condoms, your 
medication, or something else? (Brief agenda-setting) 
Mother: I want to talk about the medicine. (Change talk) 
Doctor: That’s fine, we can come back to other things. What would you most like to know 
about the medicine? (Eliciting: the start of information exchange)
Mother: If I miss taking my medicine I worry that it will bring harm. (Change talk)
Doctor: You would like to take this medicine every day. (Listening)
Patient: I want to. (Change talk)
Doctor: (Informing) It can be difficult to take the medicine at the right time each day, yet 
it is important. Even if people are feeling better and stronger, the medicine keeps them 
healthy, so it’s important to keep taking it. What’s the difficulty for you? (Eliciting the 
patient’s personal interpretation of the information)
Mother: I miss them because I hide this all from my mother, and she can see what I am 
doing all the time.
Doctor: You struggle to take them at the same time each day. (Listening)
Patient: Yes, I want to keep well (change talk), but she looks strangely at me.
Doctor: Can you think of any ways in which you can change the time and place that you 
take medicine? (Asking)
Mother: Maybe I will do this when I go to the toilet after she has gone to bed. (Change talk)
Doctor: You can see that working for you. (Listening)
Mother: It must work. I must do something like this. (Change talk)
Doctor summarises what’s been said and uses agenda setting once again to offer the patient 
a choice of talking about disclosure of her HIV status to others, improving her diet, or safe sex. 
Top 10 USEFUl qUESTIoNS
What changes would you most like to talk about? 
What have you noticed about . . .? 
How important is it for you to change . . .? 
How confident do you feel about changing . . .? 
How do you see the benefits of . . .? 
How do you see the drawback of . . .? 
What will make the most sense to you?  
How might things be different if you . . .? 
In what way . . .? 
Where does this leave you now?
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“to” or “on” patients, but “with” or “for” them. It can be 
used in any consultation about change, and evidence of 
its effectiveness is growing. It is helpful to consider your 
patient as your teacher. If he or she responds positively, 
and becomes an active participant in talk about change, 
this feedback tells you that you are doing a good job.
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An 85 year old man had a preoperative assessment for a 
knee replacement. His full blood count was normal apart 
from haemoglobin 95 g/l and mean corpuscular volume 
105 fl. He drank no alcohol. Further testing showed that 
his vitamin B-12 was low: 90 pmol/l (reference range 
160-800 pmol/l). Folate, ferritin, thyroid stimulating 
hormone, and liver function tests were normal. He had 
no other medical or surgical history and ate a balanced 
diet that includes meat.
Vitamin B-12 is found only in foods of animal origin. 
Dietary B-12 is freed from food protein by pepsin in the 
acid gastric environment and binds to haptocorrin, a 
protein secreted in saliva. In the small intestine, hap-
tocorrin is degraded by pancreatic enzymes; vitamin 
B-12 is released and binds with intrinsic factor, which is 
secreted by gastric parietal cells. This complex binds to 
receptors at the terminal ileum and is actively absorbed. 
A small fraction (1-2%) of the intake of B-12 is passively 
absorbed across the entire absorptive surface of the gas-
trointestinal tract. The recommended daily allowance of 
B-12 is small (2 µg per day) in comparison to body stores 
(2-5 mg).
What you should cover
Assess clinical evidence of B-12 deficiency
Symptoms of B-12 deficiency include neurological changes 
such as paraesthesia, numbness, ataxia, and memory loss. 
Oropharyngeal ulceration and glossitis may occur.
This is part of a series of 
occasional articles on common 
problems in primary care. The 
BMJ welcomes contributions 
from Gps
Review the medical history and drugs for possible 
causes (figure). If suggested by the history, examine for 
impaired vibration, touch, pain, and position sense and 
for ataxia.
Review the results of blood testing for macrocytic 
anaemia and neutrophil hypersegmentation, which indi-
cate B-12 deficiency. Patients may present with neuro-
logical changes of B-12 deficiency but with marginal or 
no haematological abnormalities. Coexisting iron defi-
ciency may prevent the development of macrocytosis in 
a B-12 deficient patient; if iron deficiency is suspected 
then check ferritin.
INFoRMATIoN FoR pATIENTS
Vitamin B-12 deficiency anaemia—information and 
resources on the Patient UK website (www.patient.
co.uk/health/Anaemia-(Pernicious)-and-Vitamin-B12-
Deficiency.htm)
Pernicious Anaemia Society—international society 
providing information, help, and support (www.
pernicious-anaemia-society.org)
FURThER REAdING
Galloway M, Hamilton M. Macrocytosis: pitfalls in 
testing and summary of guidance. BMJ 2007;335:884-6. 
doi:10.1136/bmj.39325.689641.471
Hvas AM, Nexo E. Diagnosis and treatment of vitamin  
B12 deficiency—an update. Haematologica 2006;91: 
1506-12.
bmj.com archive  
Previous articles in this 
series 
• Stridor in children  
(BMJ  2010;340:c2193)
• “My baby keeps bringing up 
his feeds!”  
(BMJ  2010;340:c2189)
• Hoarse voice  
(BMJ  2010;340:c522)
• Sexual health consultation 
for men who have sex with 
men (BMJ  2010;340:c958)
• Acute cough in adults  
(BMJ  2010;340:c574)
1246   BMJ | 5 June 2010 | VoluMe 340
PRACTICE
Consider referral
Refer to a gastroenterologist if malabsorption due to 
inflammatory bowel disease or coeliac disease is sus-
pected. Pregnant women with B-12 deficiency need 
urgent haematology advice, as interpreting B-12 levels 
in pregnancy is particularly difficult and B-12 deficiency 
is associated with pregnancy complications and birth 
defects.
Treatment
Hydroxocobalamin 1 mg by intramuscular injection 
three times a week for two weeks and then every three 
months.
Monitoring
Check a full blood count at eight weeks to confirm a return 
to normal haemoglobin values and cell volume. In anae-
mia needing urgent confirmation that the cause is B-12 
deficiency, a reticulocyte count one week after start of 
treatment will be markedly raised if B-12 deficiency is 
the cause. Further monitoring is not needed after haema-
tological or symptom response.
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Myelodysplasia may present with macrocytosis and 
should be suspected if macrocytosis is accompanied by 
other haematological abnormalities, such as neutropenia, 
monocytosis, thrombocytopenia, or thrombocytosis. A 
blood film should be requested and a haematology referral 
made. Myeloma may also present with macrocytosis and 
should be considered when bone pain, recurrent infec-
tion, or hypercalcaemia are present; serum electrophoresis 
should be requested.
What you should do
Decide whether your patient has clinical B-12 deficiency
Interpreting B-12 levels is difficult. Concentrations of B-12 
vary greatly between individuals and agreement between 
different commercial assays is poor: patients with clinical 
deficiency may have “normal” results on some assays and 
low results on others. Correlation between B-12 concentra-
tion and response to B-12 replacement is poor, so although 
a normal result does not rule out clinical deficiency, a low 
result does not necessarily indicate the need for treatment. 
Pregnancy and oral contraceptives can cause low B-12 lev-
els without true deficiency, and patients with underlying 
haematological disorders may have artificially high lev-
els (myeloproliferative disorders) or low levels (myeloma, 
severe neutropenia) that do not reflect true stores. Where 
there is neurological or haematological abnormality and 
low or borderline low B-12, give a course of treatment and 
reconsider ongoing replacement if there is no response.
Consider the cause 
The first step in clarifying the cause of B-12 deficiency is 
to check for pernicious anaemia (figure). Intrinsic factor 
antibodies are highly specific (nearly 100%) but poorly 
sensitive (about 60%) for pernicious anaemia. Parietal cell 
antibodies lack specificity, so are less useful. The value of 
testing where there is a probable cause (gastric surgery or 
dietary deficiency, for example), or in elderly patients with 
clear B-12 deficiency, is debated, as treatment is the same 
regardless of the underlying cause. The Schilling test is no 
longer widely available.
Macrocytosis or neurological symptoms raise the possibility of B-12 deficiency
Measure B-12 concentration
B-12 low or borderline low: check intrinsic factor
Treat B-12 deficiency and assess response
Dietary (strict vegan) Gastric, ileal, pancreatic
disease (gastric bypass,
gastrectomy, H pylori infection,
Crohn’s, coeliac disease);
pancreatic failure
Intrinsic factor positive:
confirms pernicious anaemia 
Intrinsic factor negative:
consider other causes
Patient pregnant and B-12 low:
discuss with haematologist
B-12 normal or high (B-12 deficiency unlikely): seek other causes for macrocytosis or symptoms
Drug induced (proton pump
inhibitors, H2 receptor
agonists, metformin);
chronic alcoholism
Biological competition
(bacterial overgrowth,
fish tapeworm infestation)
Assessing vitamin B-12 deficiency
“The young physician starts life with 20 drugs for each 
disease, and the old physician ends life with one drug for 
20 diseases.”
Sir William Osler (1849-1919), 
Canadian born British physician and educator
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